Supreme Court Strikes down Myriad Gene Patents in Unanimous Vote; Decision Is Expected to Benefit Clinical Pathology Laboratories

Pathologists and clinical laboratory managers can expect to see an expansion of genetic testing in the wake of the Supreme Court’s decision in the Myriad case Pathologists and clinical laboratory professionals got a major victory on June 13. That’s when the United States Supreme Court (SCOTUS) ruled 9-0 to end the 30-year-old practice of awarding patents on human genes. The unanimous decision invalidates certain hotly contested patents held by Myriad Genetics, Inc., (NASDAQ: MYGN) on the BRCA1...

Some Clinical Laboratories Report Drop in Average Number of Tests-Per-Patient

Medical laboratories and pathology groups can participate in national survey about changes in average revenue-per-requisition and average number of tests-per-requisition Across the country, a number of clinical laboratory organizations have privately told The Dark Report editorial team that they have experienced a decline in the average number of lab tests-per-requisition over the past 18 months. Since the sample size is so small, it would be inappropriate to conclude that the experience of...

Survey Set to Measure Impact of Trend by Urologists and GIs to Create Their Own In-Office Anatomic Pathology Laboratories

Medical laboratories and pathology groups lose access to tissue specimens when office-based physicians operate their own in-clinic pathology laboratory One trend reshaping the profession of anatomic pathology with surprising speed is the growth of in-clinic pathology laboratories by specialist physicians. As each office-based physician group builds its own in-clinic pathology laboratory, local pathology groups and medical laboratories lose access to the tissue specimens these doctors now...

Novartis To Pay $470 million To Buy Pathology Testing Company Genoptix

Cancer Testing and Molecular Diagnostics Are Main Drivers in This Transaction In a deal with implications for independent clinical pathology laboratories, pharmaceutical giant Novartis (NYSE: NVS) announced that it would acquire pathology testing company Genoptix, Inc. (NASDAQ: GXDX). Novartis will pay $470 million in cash to acquire all the shares of Genoptix. Although the total amount of $470 million to be paid for Genoptix is nearly one-half billion dollars, one financial analyst who...
;